PSYK seeks to replicate, to the extent possible and. Reid Robison, as well as his special Bicycle Day guest post. Following their fast entry additions into the Index, Mindset Pharma and Novamind have been, or will be, added as constituent holdings of PSYK. Make sure to check out some of our previous interviews with Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University and is the founder of the Polizzi Free Clinic, a free mental health clinic for marginalized people based in Salt Lake City, Utah. Robison has built a number of purpose-driven companies including Tute Genomics which was acquired by PierianDx in 2016. Robison has guided thousands of ketamine therapy journeys and hundreds of Spravato™ dosing sessions. 9 min read Transaction has completed following shareholder and court approvals Novamind shareholders and RSU holders have been issued 0.84 Numinus shares per Novamind. Robison led a pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato™. As an early adopter and researcher of ketamine in psychiatry, Dr. He is currently the coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. Robison is the co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading Eating Disorder center. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly’s Best of Utah Body & Mind 2020. You can find Novamind on Twitter, Instagram, and LinkedIn.ĭr. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visitnovamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Joining James and Reid are KAP patients Jen Cope and Ryan Perez, who speak about their experience. Reid Robison, Chief Medical Officer of Novamind, to discuss a pilot program providing free-of-cost ketamine-assisted psychotherapy (KAP) to frontline workers affected by COVID-19 in Utah and Colorado. Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.In our first installment of Truffle Talks, James sits down with Dr. “With our strong wellness clinic network and a growing clinical research division, Numinus is one of the best-positioned companies in the sector – supported by diversified revenue streams, growing brand awareness, and a recognized pathway to profitability,” Nyquvest said. Numinus CEO Payton Nyquvest said fiscal 2022 was a pivotal year for Numinus as it entered the US market with its acquisition of Novamind, expanded its ketamine-assisted therapy offering across Canada, launched a formal practitioner training program, and unveiled a global rebranding of the company. Its gross profit for fiscal 2022 was $1.8 million, up from a loss of $81,538 in fiscal 2021. READ: Numinus Wellness unveils revamped podcast series with additional hosts and expanded topicsįor fiscal 2022, Numinus posted a 329% increase in revenues from $1.5 million in fiscal 2021 to $6.5 million, which the company attributed primarily to acquisitions completed during the year. The float and shares outstanding we use are sourced from Capital IQ. The company generated $1.3 million in profit during 4Q compared to a $89,674 loss in the year-ago quarter. NVMDF - Short Interest - NOVAMIND INC Stock - Short Squeeze, Borrow Rates. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Numinus Wellness Inc said its fourth quarter results have demonstrated the power of its larger, cross-broader platform following the completion of its acquisition of Novamind earlier this year.įor 4Q, which ended on August 31, 2022, the integrated mental healthcare company providing psychedelic-assisted therapies reported a 643% jump in revenue to $4.2 million, up from $487,899 for the same period last year.
0 Comments
Leave a Reply. |